repurchas help davita consensu boost
page full analyst note
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim aug
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
narrow moat stem domin essenti
posit dialysi market account one third
dialysi facil patient treatment
much investor concern last year ultim stem
industri structur levi industrywid profit
small hand commerci insur patient caution
investor lose sight bigger pictur provid
lifesav healthcar servic chronic ill patient
lower-cost outpati set sinc altern outpati
dialysi higher cost less effici burdensom acut
therapi see littl likelihood falter due regulatori
disrupt long term think continu scrutini
patient assist program could caus pain industri
potenti chang limit patient abil continu
commerci plan time howev think would catalyz
industri consolid leav compar
advantag posit versu smaller independ peer lack
cost advantag present oper would also
highlight medicar scenario repres dire albeit
low probabl scenario dialysi player
put asid present concern industri take
favor view manag recent sale davita
medic group asset long drag profit return
capit busi perenni under-perform follow
acquisit absent major structur chang dialysi
reimburs polici anticip return capit
improv manag focus scale intern
presenc without distract dmg assess
manag capit alloc prowess
somewhat
tarnish experi dmg plan use
billion proce debt reduct stepped-up share
repurchas look like value-cr capit deploy option
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
largest provid dialysi servic boast market
share level eclips measur patient clinic
firm oper facil world-wide unit state
treat patient global year manag began
build fledgl intern busi anticip
busi need continu expand garner scale need
earn attract return govern payer domin dialysi
reimburs -- receiv approxim sale
medicar medicaid reimburs rate remain
come commerci insur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repurchas help davita consensu boost
narrow-moat turn strong third-quart result
consensu estim capit iq led
firm boost outlook share rise
after-hour trade still view moder
under-valued rel fair valu estim overal
view quarter result favor
organ pressur regulatori
concern year
first quarter sell davita medic group
dmg turn billion sale growth
year year slightli consensu billion
normal organ patient volum growth
similar firm revenu growth compani cost
control effort share repurchas led strong rise
per share grew consensu
particular pleas see continu share
repurchas discount price reduc
firm share count sinc dmg sale close
june quarter repurchas billion
share averag share price per share
discount fair valu estim
strong underli result abl
increas outlook davita
expect least million adjust oper
profit new rang billion
increas cash flow expect includ higher
oper cash flow rang billion
billion previous reduc capit
expenditur expect new rang million-
million million previous
expect earn per
share new rang primarili
reduc share count expect off-set somewhat cost
relat ballot initi
fair valu estim per share
impli time estim adjust
earn ebitda respect
forecast call roughli growth
domest dialysi servic oper contempl
treatment growth near revenu per treatment
approxim basi point five-year forecast
horizon volum assumpt impli modest share
gain period gain roughli basi
point share patient given
matur segment think increment margin gain
difficult come model flat oper
margin importantli assum materi
profit impact on-going concern regard
premium assist across industri legisl
propos ballot initi california
fail garner broad-bas support result risk
cash flow appear retreat
surpris ultim last
regulatori effort target dialysi industri
firm intern dialysi busi estim
revenu growth nearer low mid-teen rate
forecast period manag focus invest
segment driven double-digit growth total
number clinic oper annual price
improv averag time busi
gain scale estim meaning improv
profit break-even slightli profit level
forecast ebitda margin roughli
believ ampl room exist continu expans
matur level like low mid-teen
although expos sizabl low-prob risk
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
growth nearer basi point lower
base-cas forecast case expect firm
oper increas treatment volum line total
esrd patient growth overal per-treat price
see basi point declin compound annual
basi incorpor modest impact
propos chang patient access ebitda
forecast roughli lower base case
estim price pressur cost inflat combin
reduc dialysi margin approxim basi
point intern segment lower level
invest new facil cost pressur result
modest profit low singl digit
lead total compani oper margin
histor low estim culmin fair valu
estim per share time lower
earn ebitda estim respect
believ peer freseniu medic
benefit scale-deriv cost advantag thank
domin global dialysi market combin
estim two entiti account greater
dialysi market unit state measur
either clinic oper patient treat level
scale provid per-unit cost advantag firm
along materi negoti power contract
commerci insur crucial sustain
earn excess return industri
treat patient unit state
current requir mainten
although home-bas treatment exist
gain margin share time in-cent treatment
gruel requir three center visit per week hour
rest patient life receiv
kidney transplant result dialysi industri
continu expand overal facil count build
view think deserv medium
bull-cas scenario think firm consolid
revenu grow roughli approxim basi
point better base-cas estim help
treatment growth nearer better
price environ lead growth annual
per-treat price averag forecast period
addit aggress
intern market lead high teen revenu growth
rate segment faster growth less restrict
price environ allow better-than-expect margin
perform estim basi point
oper ebitda margin expans firm
domest dialysi segment bull-cas assumpt
lead consolid oper margin
roughli near histor high busi
incorpor assumpt result fair valu
estim per share time higher
estim earn ebitda respect
bear-cas assumpt result total compani revenu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
capac keep pace patient growth
also improv conveni number
facil unit state stood roughli
approxim compound annual
growth rate period estim
par overal growth rate preval end-stag
renal diseas esrd case sinc
mani healthcar provid coverag
govern payer medicar medicaid
repres largest payer nation unlik
compani coverag esrd diseas state
automat qualifi
medicar coverag
regardless patient age circumst patient
allow earli
enrol medicar month initi diagnosi
creat uniqu reimburs environ
make negoti commerci payer vastli
import tradit healthcar provid
explain dialysi servic becom highli
concentr industri versu fragment seen
area acut care aggreg govern
reimburs estim provid neg
break-even margin thu profit industri level
must extract commerci insur earn
roughli two third revenu government-bas
payer third commercial-pay patient
said estim patient mix even lopsid
roughli patient base commerci
insur medicar per treatment base
payment rate estim commerci
reimburs fall north abil earn
reimburs rate nearli time
govern will pay indic substanti
negoti leverag view
cost side equat industri benefit
scale high capac util accord medpac
lowest-volum facil oper medicar cost
per treatment north highest-volum
oper benefit cost closer
annual place estim averag cost medicar
patient somewher per treatment
help valid profit estim payer
suggest
medicar busi break-even best even largest
provid space freseniu oper
best-in-class util level help improv unit
econom -- two largest provid oper roughli
firm-wide capac averag versu rest
industri oper littl
view advantag two-sid scale
earn best-in-class reimburs
commerci insur also provid procur
effici support firm consist midteen
recent sold medic group busi
view divestitur posit
firm abl get decent price asset think
would deserv no-moat rate billion versu
billion paid acquir best
estim put dmg return capit midsingl
digit declin sinc initi bought
busi think addit asset one
major factor behind compani weaker return
profil sinc estim suggest return
focu core dialysi busi quickli improv
expect firm profil improv follow
divestitur davita medic group believ core
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
element underpin firm cost advantag
dialysi remain stabl time estim
firm continu increas share unit state
expand facil base addit break-even
intern busi like contribut
enterpris time achiev relev scale davita
better abl leverag invest made
date reimburs uncertainti unlik
fade given dynam industri think davita
retain posit low end cost curv
key reduc cost improv outcom
treatment esrd
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
benefit long-term tailwind
grow global esrd patient popul
preval diabet hypertens continu
market-lead posit ensur
benefit low-cost oper industri
becom increasingli hostil subscal provid
ounderpenetr intern market quickli
becom largest esrd market world
oper allow continu growth
owith except high relianc commerci
reimburs profit industri would
neg affect payer-system
chang substanti includ medicar
oalthough medicar rate updat trend
posit late recent net payment
updat like still overal cost inflat
experienc servic provid
opotenti chang govern polici regard
toward patient assist program keep
patient commerci insur plan longer could
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
think firm oper respons leverag
profil given high consist busi gross
debt level typic rang time adjust
ebitda billion sale dmg complet
manag intend recapit busi roughli
billion earmark date share repurchas
remaind lower firm debt burden roughli
consist prior expect model still
impli year-end leverag time adjust
ebitda howev note leas nearli
dialysi clinic creat off-balance-sheet oper
leas oblig total roughli billion
estim reimburs pressur pose acut risk
dialysi provid unseen elsewher healthcar
provid sector given industri relianc small
segment overal esrd patient popul maintain
profit oper remain key oper
risk think superior cost posit help insul
advers market condit compar smaller
fragment independ competitor
although expos sizabl low-prob risk
think deserv medium uncertainti rate
view relat critic natur servic davita
provid expand patient popul unilater
reimburs pressur remain key risk
industri howev think firm substanti scale
ensur well-posit mitig headwind
aris potenti reimburs cut reduc patient
coverag commerci insur like
scenario exclud medicar
technolog risk like gener headlin
come year think wholesal transit away
in-cent hemodialysi primari treatment modal
unlik signific comorbid patient popul
skew older make widespread adopt
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
home-bas therapi difficult view like gain
share margin technolog continu advanc
becom patient-friendli see
major risk core oper also
appeal court struck propos rulemak
center medicar medicaid servic relat limit
dialysi patient access premium assist program
recent propos legisl california state
threaten enact similar barrier patient access
similar initi fail gain traction think
like see futur propos target dialysi
industri given outsiz per-pati cost structur
probabl on-going risk profit
believ superior cost posit allow weather
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
share
fund
share
fund
give javier rodriguez rest manag
team standard mark capit stewardship
think team done except job
develop firm domin posit dialysi
market unit state think foray broader
physician practic manag purchas
healthcar partner rais red flag
year reimburs pressur leadership turnov
busi restructur happi see manag
enter agreement sell busi nearli
billion said fail invest coordin
care leav us skeptic relat futur capit
alloc manag intend use cash windfal
pay debt repurchas share two use capit
think benefit sharehold long run given
firm current market valuat interest
manag invest prioriti without distract
dmg segment -- prefer see bulk
no-moat intern dialysi oper make
anoth attempt diversifi area healthcar
fan compens structur put place
compani board believ well-suit
hold manag account sharehold valu
creation manag annual bonu tie clinic
outcom oper incom think critic
measur success long-term incent pay
execut offic split perform share
time-bas award half tie metric
adjust earn rel total sharehold return
half subject time-bas vest schedul
said like see insid ownership
upper level manag particularli given member
long tenur firm -- whole director offic
group hold less equiti stake
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
report second-quart result line
preliminari figur releas last week although
manag provid increment detail regard
driver out-performance oper incom line
like lower per share fair valu estim
low-single-digit percentag adjust benefit
attribut gener calcimimet avail
recur next year reimburs chang
match lower price howev narrow-moat firm
remain deepli discount best idea within
standout quarter cost-per-treat
declin sequenti year-over-year basi
manag call product posit
calcimimet cost declin far primari factor
lower epogen price also like play role
report sale drug nearli
quarter
benefit asid growth remain much lower
anticip non-acquir treatment growth
quarter expect continu near second-
half given much stronger perform freseniu
medic date clear firm cede
market share last sever quarter although
manag also suggest industrywid growth
industri elect cycl remind
proposit california ultim vote
elect cost million
polici news manag provid addit
commentari kidney-car execut order put
trump administr earlier juli firm
outlook home dialysi broadli goal
patient receiv home care line
high end penetr assumpt
outlin prior content attract dialysi
impli least lower de novo clinic
construct activ respons potenti effect
growth home dialysi might in-cent
capac util manag mix shift without see
increas slack exist clinic network critic
maintain strong per-treat econom
encourag see manag proactiv
dutch auction tender share jul
upcom second-quart releas boost
oper incom guidanc full year addit
firm announc intent tender billion stock
dutch auction process expect adjust
fair valu estim yet reassess
outlook firm post full earn releas
shape unexpectedli strong year
headwind appear like prevail declin
calcimimet reimburs reason well
understood although make tough oper incom
compar much year importantli
manag warn surpris see
return variou ballot initi target dialysi
applaud manag decis aggress buy
back stock sever discount valuat
repurchas program complet price
depend sharehold elect
tender high end rang would account
nearli firm equiti price impli
valuat multipl roughli time adjust
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
earn forecast addit manag
announc compani alreadi acquir
addit million stock per share sinc
first-quart earn call may addit
approxim current outstand share
count year valuat near rate
excel use capit receiv sale
davita medic group view
tender
opportun
manag boost annual oper incom guidanc
billion nearli million
midpoint compar favor current
billion estim bulk upsid driven better-
than-expect avail gener calcimimet drug
year date expect recur next year
howev nearli million math attribut
growth continu fall short expect
trump administr propos chang dialysi
juli presid donald trump sign execut
order focus improv kidney health american
tandem center medicar medicaid servic
propos four new payment model govern dialysi
reimburs three program
voluntari effect extens expans
exist comprehens esrd model
set run importantli mandatori
esrd treatment choic model etc bring sweep
incent program intend cover half medicare-
demonstr program alter narrow moat
rate freseniu medic
forese major adjust fair valu estim
pars long-term implic propos
etc program creat financi incent dialysi
facil practic clinician either prescrib home
dialysi facilit organ transplant first three
year program includ low-single-digit
percentag increas reimburs rate paid
medicar home therapi session
phase time replac two-sid risk
program start particip facil
clinician see either posit neg payment
adjust tie score system encourag
util home therapi better transplant rate
scale use measur improv --
particip evalu rel either baselin
rate establish specif entiti benchmark
rate comparison geograph area
asid payment reform trump order also aim
work list nearli peopl await
kidney transplant better compens live donor
improv organ util administr hope
nearli doubl avail kidney
deeper analysi econom home dialysi
therapi pleas see report attract dialysi
unit under-valued jun
market close june feder trade
commiss releas detail complaint
agreed-to settlement
group satisfi anti-trust concern stem unit
purchas davita medic group announc
bring roughli year-and-a-half transact process
close receiv report sale price
billion asset anticip cash infus
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
go toward debt reduct share repurchas
near termact applaud given steep discount
versu per share fair valu estim intend
alter valuat narrow- wide-moat rate
either unit respect result deal
ftc object base concentr market
power nevada unit particularli strong
insur presenc specif unit purchas
dmg la vegas-area medic practic would put
optumcar posit cover roughli medicar
advantag member region creat incent
anticompetit action contract area
parti agre divest practic
intermountain healthcar within next day
remedi alleg effect
conclus process mark first bit posit
news best idea davita time
transact final manag given flexibl
shore firm balanc sheet path toward
oper improv derisk capit
structur perspect continu see sizabl upsid
share current level believ share repres one
compel opportun healthcar
sector long-term investor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
incom equiti invest
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
